News & Updates

Patients receiving the combination of letermovir and tacrolimus with concomitant moderate cytochrome P450 (CYP) 3A4 inhibitors show a decline in tacrolimus dosing requirements, a study has shown.

Subcutaneous prophylactic treatment with garadacimab significantly reduced the monthly number of attacks and led to attack-free status as early as week 1 in patients with hereditary angioedema (HAE) in the post hoc analysis of the phase III VANGUARD study presented at ACAAI 2023.

Initiation of vaginal micronized progesterone during the first trimester appears to reduce the risk of hypertensive disorders of pregnancy (HDP) and pre-eclampsia, according to a study.

Many primary care physicians (PCPs) appear to be inadequately informed about the role of biologics in managing asthma, as shown in a study.

Twelve-month treatment with zoledronate significantly increases bone mineral density (BMD) Z-scores without affecting growth in nonambulant children with cerebral palsy (CP), reports a study. However, side effects of the first dose are common.

In the treatment of patients with lupus nephritis, adding obinutuzumab to standard-of-care therapy is more efficacious than standard-of-care therapy alone in preventing flares and preserving kidney function, according to a study.

Among Chinese patients with hypertension, a 48-month intensive blood pressure (BP) intervention programme significantly reduces the risk of developing dementia than usual care, according to a study presented at AHA 2023.